EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Cannabinoids for Behavioral Symptoms in Dementia: An Overview

Barbara Broers, Federica Bianchi

Pharmacopsychiatry · 01.05.2024 · 57 (03) · 160-168

DOI: 10.1055/a-2262-7837 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmacopsychiatry, erschienen am 01.05.2024. Verfasst von Barbara Broers und 1 weiteren Autor:innen. Beteiligte Einrichtung: Geneva University Hospitals, Primary Care Division, Geneva, Switzerland. Hauptthemen laut MEDLINE: Dementia, Cannabinoids. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dementia, with loss of memory, cognitive abilities, and independent daily functioning, is increasing worldwide, related to an aging population. Currently, there is no curative treatment for dementia. Treatment of the frequently occurring behavioral and psychological symptoms of dementia (BPSD) is partially effective and associated with significant side effects. Cannabinoids are lipophilic molecules acting on the CB1 end CB2 receptors, essential for main biological processes such as sleep, appetite, memory, and pain. Cannabinoids might have a positive impact on amyloid formation in Alzheimer’s disease, the main form of dementia, and on BPSD symptoms. Most knowledge currently concerns delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). In the context of dementia and BPSD, THC might be beneficial for associated spasticity and possible pain or lack of appetite and CBD probably works better on sleep, agitation, and anxiety. This overview of prospective clinical studies and randomized clinical trials, published between 2005 and April 2023, using cannabinoids for BPSD suggests that older studies using low-dose oral synthetic THC showed no positive results. Still, more recent studies using THC/CBD-based oral medication at higher doses show promising results and are feasible and safe in this elderly polymedicated population. Several RCTs are ongoing and planned worldwide, and we hope other trials will follow to establish clinical efficiency and optimal dosing, as well as other outcomes such as deprescribing other medications and facilitation of care. We suggest that researchers also address the more sociological aspects of prescribing cannabinoids for dementia and BPSD in their specific context.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DementiaCannabinoidsHumansBehavioral SymptomsCannabidiolDronabinol

Substanzen

CannabinoidsCannabidiolDronabinol

Autor:innen und Institutionen

  • Geneva University Hospitals, Primary Care Division, Geneva, Switzerland.
  • Geneva University Hospitals, Palliative Care Division, Geneva, Switzerland.

Zitieren

APA

Broers, B., & Bianchi, F. (2024). Cannabinoids for Behavioral Symptoms in Dementia: An Overview. Pharmacopsychiatry, 57(03), 160-168. https://doi.org/10.1055/a-2262-7837

Vancouver

Broers B, Bianchi F. Cannabinoids for Behavioral Symptoms in Dementia: An Overview. Pharmacopsychiatry. 2024;57(03):160-168. doi:10.1055/a-2262-7837

BibTeX
@article{Broers2024,
  author = {Broers, Barbara and Bianchi, Federica},
  title = {Cannabinoids for Behavioral Symptoms in Dementia: An Overview},
  journal = {Pharmacopsychiatry},
  year = {2024},
  volume = {57},
  number = {03},
  pages = {160--168},
  doi = {10.1055/a-2262-7837}
}
Kostenlos starten →